Arrowhead Research Corporation's Nanotope, a Pasadena, Calif.-based medical research organization, entered into an agreement with Smith & Nephew to develop cartilage regeneration products, according to an Arrowhead news release.
Under the agreement, Smith & Nephew will fund and conduct preclinical tests required to support clinical trials, purchase preclinical material from Nanotope and assume all clinical trial costs. Nanotope stands to receive up to $26.55 million in milestone payments and sales royalties.
Nanotope's products include regeneration for neuronal, vascular, bone and myocardial tissue, which aims to prevent and reverse paralysis associated with spinal cord injury, advance wound healing and provide treatment for peripheral artery diseases.
Read the Arrowhead release on the agreement.
Read other coverage on device company partnerships:
- Osseon Therapeutics, DePuy Spine Form a Distribution Agreement
- Medtronic Distributes Tissuemed's Obex NeuroFilm
- Zimmer, Accentus Medical Sign Technology Agreement
Under the agreement, Smith & Nephew will fund and conduct preclinical tests required to support clinical trials, purchase preclinical material from Nanotope and assume all clinical trial costs. Nanotope stands to receive up to $26.55 million in milestone payments and sales royalties.
Nanotope's products include regeneration for neuronal, vascular, bone and myocardial tissue, which aims to prevent and reverse paralysis associated with spinal cord injury, advance wound healing and provide treatment for peripheral artery diseases.
Read the Arrowhead release on the agreement.
Read other coverage on device company partnerships:
- Osseon Therapeutics, DePuy Spine Form a Distribution Agreement
- Medtronic Distributes Tissuemed's Obex NeuroFilm
- Zimmer, Accentus Medical Sign Technology Agreement